Marshall Stanton Sells 1,259 Shares of Artivion (NYSE:AORT) Stock

Artivion, Inc. (NYSE:AORT) SVP Marshall Stanton sold 1,259 shares of Artivion stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $35.69, for a total transaction of $44,933.71. Following the sale, the senior vice president owned 41,921 shares of the company’s stock, valued at approximately $1,496,160.49. This represents a 2.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Artivion Trading Up 0.9%

Shares of NYSE:AORT traded up $0.31 during mid-day trading on Wednesday, reaching $35.66. 300,261 shares of the company were exchanged, compared to its average volume of 399,410. Artivion, Inc. has a 1 year low of $21.97 and a 1 year high of $48.25. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.53 and a quick ratio of 2.62. The firm’s 50-day simple moving average is $42.51 and its 200 day simple moving average is $43.14. The firm has a market cap of $1.71 billion, a price-to-earnings ratio of 178.32 and a beta of 1.59.

Artivion (NYSE:AORT) last released its quarterly earnings results on Thursday, February 12th. The company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.03. Artivion had a return on equity of 7.43% and a net margin of 2.21%.The company had revenue of $118.30 million for the quarter, compared to analysts’ expectations of $116.42 million. The firm’s revenue for the quarter was up 19.2% compared to the same quarter last year. Equities research analysts forecast that Artivion, Inc. will post 0.37 EPS for the current year.

Analysts Set New Price Targets

AORT has been the subject of a number of research analyst reports. Oppenheimer restated an “outperform” rating and set a $50.00 target price on shares of Artivion in a report on Friday, November 7th. Weiss Ratings raised shares of Artivion from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, February 20th. Canaccord Genuity Group dropped their price objective on shares of Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a report on Friday, February 13th. Citizens Jmp upped their target price on shares of Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a research note on Friday, November 7th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $58.00 price target on shares of Artivion in a research report on Monday, February 2nd. Six investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $48.97.

Hedge Funds Weigh In On Artivion

Institutional investors and hedge funds have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd purchased a new position in Artivion in the third quarter valued at $27,000. Aster Capital Management DIFC Ltd boosted its position in shares of Artivion by 402.3% during the 3rd quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock worth $27,000 after acquiring an additional 519 shares in the last quarter. Larson Financial Group LLC increased its holdings in shares of Artivion by 148.5% in the 4th quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock valued at $43,000 after acquiring an additional 563 shares during the last quarter. USA Financial Formulas raised its position in shares of Artivion by 163.5% during the 4th quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock worth $52,000 after acquiring an additional 703 shares in the last quarter. Finally, KBC Group NV purchased a new stake in Artivion during the fourth quarter worth approximately $65,000. Institutional investors and hedge funds own 86.37% of the company’s stock.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.